Repurposing pharma assets: an accelerated mechanism for strengthening the schistosomiasis drug development pipeline

Schistosomiasis, one of 17 diseases deemed to be neglected by the World Health Organization, has received little attention from the biopharmaceutical industry. Due to this, only a handful of drugs have been developed to treat schistosomiasis, with only one, praziquantel, used in most endemic regions...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Future medicinal chemistry 2015-01, Vol.7 (6), p.727-735
Hauptverfasser:	Ramamoorthi, Roopa, Graef, Katy M, Dent, Jennifer
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Anthelmintics - economics Anthelmintics - pharmacology Cost-Benefit Analysis Drug Repositioning - economics Drug Repositioning - methods Humans Neglected Diseases - drug therapy Neglected Diseases - economics Schistosoma - drug effects Schistosomiasis - drug therapy Schistosomiasis - economics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!